Drug intelligence / Profile preview

rimonabant

Development stage: Phase 4
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Rimonabant is a small molecule anorectic anti-obesity drug developed by Sanofi. It acts as an inverse agonist and antagonist of the cannabinoid receptor 1 (CB1), primarily in the central nervous system, leading to reduced appetite and food intake. Rimonabant was the first selective CB1 receptor blocker approved for use globally, with its main indication being obesity. It was also studied for type 2 diabetes, atherosclerosis, and smoking cessation. However, due to serious psychiatric side effects such as depression and suicidality, it was withdrawn from all markets worldwide[1][2][3][4][5][7][8].

Brand names: AcompliaZimulti
Other names: rimonabantSR141716ASR-141716ASR 141716A

Targets

CNR1 (Cannabinoid receptor 1)MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on rimonabant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rimonabant.

Explore the full profile